Erenumab in migraine: Indication of considerable added benefit for certain patients
Erenumab was the first drug of a new drug class for the prophylaxis of migraine to enter the German market in November 2018. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) ...
Feb 7, 2019
0
1